Related references
Note: Only part of the references are listed.Activating cGAS-STING pathway for the optimal effect of cancer immunotherapy
Anping Li et al.
JOURNAL OF HEMATOLOGY & ONCOLOGY (2019)
Immunogenic chemotherapy: Dose and schedule dependence and combination with immunotherapy
Junjie Wu et al.
CANCER LETTERS (2018)
PD-L1 expression is mainly regulated by interferon gamma associated with JAK-STAT pathway in gastric cancer
Kousaku Mimura et al.
CANCER SCIENCE (2018)
Anti-PD-1 therapy in patients with advanced melanoma and preexisting autoimmune disorders or major toxicity with ipilimumab
A. M. Menzies et al.
ANNALS OF ONCOLOGY (2017)
Rational Selection of Syngeneic Preclinical Tumor Models for Immunotherapeutic Drug Discovery
Suzanne I. S. Mosely et al.
CANCER IMMUNOLOGY RESEARCH (2017)
Poly-isoprenylated ifosfamide analogs: Preactivated antitumor agents as free formulation or nanoassemblies
Charles Skarbek et al.
INTERNATIONAL JOURNAL OF PHARMACEUTICS (2017)
cGAS is essential for the antitumor effect of immune checkpoint blockade
Hua Wang et al.
PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA (2017)
Enhanced antitumor effects by combining an IL-12/anti-DNA fusion protein with avelumab, an anti-PD-L1 antibody
Jonathan K. Fallon et al.
ONCOTARGET (2017)
CD11b regulates the Treg/Th17 balance in murine arthritis via IL-6
Mathias Stevanin et al.
EUROPEAN JOURNAL OF IMMUNOLOGY (2017)
CCR2 Influences T Regulatory Cell Migration to Tumors and Serves as a Biomarker of Cyclophosphamide Sensitivity
Pierre-Louis Loyher et al.
CANCER RESEARCH (2016)
Immunogenic Chemotherapy Sensitizes Tumors to Checkpoint Blockade Therapy
Christina Pfirschke et al.
IMMUNITY (2016)
The EGFR pathway is involved in the regulation of PD-L1 expression via the IL-6/JAK/STAT3 signaling pathway in EGFR-mutated non-small cell lung cancer
Nan Zhang et al.
INTERNATIONAL JOURNAL OF ONCOLOGY (2016)
Chemotherapy Induces Programmed Cell Death-Ligand 1 Overexpression via the Nuclear Factor-κB to Foster an Immunosuppressive Tumor Microenvironment in Ovarian Cancer
Jin Peng et al.
CANCER RESEARCH (2015)
Doxil Synergizes with Cancer Immunotherapies to Enhance Antitumor Responses in Syngeneic Mouse Models
Jonathan Rios-Doria et al.
NEOPLASIA (2015)
Preactivated Oxazaphosphorines Designed for lsophosphoramide Mustard Delivery as Bulk Form or Nanoassemblies: Synthesis and Proof of Concept
Charles Skarbek et al.
JOURNAL OF MEDICINAL CHEMISTRY (2015)
Immune-based mechanisms of cytotoxic chemotherapy: implications for the design of novel and rationale-based combined treatments against cancer
L. Bracci et al.
CELL DEATH AND DIFFERENTIATION (2014)
Cyclophosphamide Compared With Ifosfamide in Consolidation Treatment of Standard-Risk Ewing Sarcoma: Results of the Randomized Noninferiority Euro-EWING99-R1 Trial
Marie-Cecile Le Deley et al.
JOURNAL OF CLINICAL ONCOLOGY (2014)
Pathogenic conversion of Foxp3(+) T cells into T(H)17 cells in autoimmune arthritis
Noriko Komatsu et al.
NATURE MEDICINE (2014)
Rationale for targeting the immune system through checkpoint molecule blockade in the treatment of non-small-cell lung cancer
C. Zielinski et al.
ANNALS OF ONCOLOGY (2013)
Chemoimmunotherapy: reengineering tumor immunity
Gang Chen et al.
CANCER IMMUNOLOGY IMMUNOTHERAPY (2013)
The Intestinal Microbiota Modulates the Anticancer Immune Effects of Cyclophosphamide
Sophie Viaud et al.
SCIENCE (2013)
Metronomic cyclophosphamide treatment in metastasized breast cancer patients: immunological effects and clinical outcome
Yingzi Ge et al.
CANCER IMMUNOLOGY IMMUNOTHERAPY (2012)
Cyclophosphamide inhibits the generation and function of CD8+ regulatory T cells
Ilaria Traverso et al.
HUMAN IMMUNOLOGY (2012)
Exploitation of the propulsive force of chemotherapy for improving the response to cancer immunotherapy
Enrico Proietti et al.
MOLECULAR ONCOLOGY (2012)
Cyclophosphamide Induces Differentiation of Th17 Cells in Cancer Patients
Sophie Viaud et al.
CANCER RESEARCH (2011)
Cyclophosphamide Synergizes with Type I Interferons through Systemic Dendritic Cell Reactivation and Induction of Immunogenic Tumor Apoptosis
Giovanna Schiavoni et al.
CANCER RESEARCH (2011)
Th17 cells in cancer: help or hindrance?
Cailin Moira Wilke et al.
CARCINOGENESIS (2011)
High-Dose Ifosfamide as Second- or Third-Line Chemotherapy in Refractory Bone and Soft Tissue Sarcoma Patients
Soo Hyeon Lee et al.
ONCOLOGY (2011)
Oxazaphosphorines: new therapeutic strategies for an old class of drugs
Berenice Giraud et al.
EXPERT OPINION ON DRUG METABOLISM & TOXICOLOGY (2010)
Improved Survival with Ipilimumab in Patients with Metastatic Melanoma
F. Stephen Hodi et al.
NEW ENGLAND JOURNAL OF MEDICINE (2010)
Indoleamine 2,3-dioxygenase controls conversion of Foxp3+ Tregs to TH17-like cells in tumor-draining lymph nodes
Madhav D. Sharma et al.
BLOOD (2009)
Toxic effects of different doses of cyclophosphamide on the reproductive parameters of male mice
Tatiane Yumi Nakamura Kanno et al.
BRAZILIAN JOURNAL OF PHARMACEUTICAL SCIENCES (2009)
Tumor-induced immune suppression of in vivo effector T-cell priming is mediated by the B7-H1/PD-1 axis and transforming growth factor β
Shuang Wei et al.
CANCER RESEARCH (2008)
Differential effects of ifosfamide on dendritic cell-mediated stimulation of T cell interleukin-2 production, natural killer cell cytotoxicity and interferon-γ production
M. C. Kuppner et al.
CLINICAL AND EXPERIMENTAL IMMUNOLOGY (2008)
Ups and downs: The STAT1:STAT3 seesaw of Interferon and gp130 receptor signalling
Gabriella Regis et al.
SEMINARS IN CELL & DEVELOPMENTAL BIOLOGY (2008)
Tumor microenvironment: The role of the tumor stroma in cancer
Hanchen Li et al.
JOURNAL OF CELLULAR BIOCHEMISTRY (2007)
Defining the ability of cyclophosphamide preconditioning to enhance the antigen-specific CD8(+) T-cell response to reptide vaccination: Creation of a beneficial host microenvironment involving type IIFNs and myeloid cells
Mohamed L. Salem et al.
JOURNAL OF IMMUNOTHERAPY (2007)
Chemoimmunotherapy of tumors:: Cyclophosphamide synergizes with exosome based vaccines
Julien Taieb et al.
JOURNAL OF IMMUNOLOGY (2006)
Gemcitabine selectively eliminates splenic Gr-1+/CD11b+ myeloid suppressor cells in tumor-bearing animals and enhances antitumor immune activity
E Suzuki et al.
CLINICAL CANCER RESEARCH (2005)
Inhibition of CD4+25+ T regulatory cell function implicated in enhanced immune response by low-dose cyclophosphamide
MEC Lutsiak et al.
BLOOD (2005)
High-dose ifosfamide in relapsed pediatric osteosarcoma: Therapeutic effects and renal toxicity
SG Berrak et al.
PEDIATRIC BLOOD & CANCER (2005)
CD4+CD25+ regulatory T cells suppress tumor immunity but are sensitive to cyclophosphamide which allows immunotherapy of established tumors to be curative
F Ghiringhelli et al.
EUROPEAN JOURNAL OF IMMUNOLOGY (2004)
Clinical pharmacokinetics and pharmacodynamics of ifosfamide and its metabolites
T Kerbusch et al.
CLINICAL PHARMACOKINETICS (2001)
Prospective randomized clinical trial comparing high-dose ifosfamide plus GM-CSF vs high-dose cyclophosphamide plus GM-CSF for blood progenitor cell mobilization
J Vela-Ojeda et al.
BONE MARROW TRANSPLANTATION (2000)
Effect of high-dose ifosfamide in advanced soft tissue sarcomas. A multicentre phase II study of the EORTC Soft Tissue and Bone Sarcoma Group
OS Nielsen et al.
EUROPEAN JOURNAL OF CANCER (2000)
Share Paper
